Fluence by OSRAM Reveals Multiyear Global Research Results on Broad-Spectrum Lighting Strategies for Cannabis and Food Crops
12.8.2021 15:00:00 EEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today the results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on cannabis, Merlice tomatoes and bell peppers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005279/en/
Fluence by OSRAM announced results from a series of multiyear global studies analyzing the effects of broad-spectrum white light on plant yield, morphology, development and quality in cannabis, Merlice tomato and bell pepper crops. (Photo: Business Wire)
The studies found that while spectrum sensitivity is cultivar-dependent, broad-spectrum lighting strategies—which include green light and other wavelengths largely absent in narrow-band spectra—improved crop yield, morphology and overall performance in selected cultivars when compared to narrow-band spectra with high ratios of red and far-red wavelengths.
“The results from our global studies show how effective broad-spectrum white light can be in improving crop performance for many cultivators around the world,” said Dr. David Hawley, principal scientist at Fluence. “Broad-spectrum strategies are about balance and flexibility in the spectrum itself as well as the overall cultivation approach. While there are certain scenarios in which narrow-band spectra, or pink light, may make sense from an energy efficiency or crop production perspective, we’ve found that many cultivars simply perform better under broad spectra across the KPIs cultivators care about most: yield, morphology and overall quality. Our latest research empowers us with new insights to assess each grower’s objectives, weigh those objectives against a facility’s unique financial, environmental and energy parameters, and then ultimately derive a tailored solution for each cultivator.”
Merlice tomatoes
A collaborative study with Wageningen University and Research (WUR)—led by researchers Leo Marcelis and Ep Heuvelink—evaluated differences in yield, morphology, development and quality for Merlice tomatoes grown with the VYPR top light series under four light spectra: PhysioSpecTM BROAD R4, PhysioSpec TM BROAD R6, PhysioSpecTM BROAD R8 and PhysioSpecTM DUAL R9B. BROAD R4, R6 and R8 all contain significant fractions of green light and other photosynthetically active wavelengths, while DUAL R9B is a narrow-band spectrum that contains almost no green light.
As researchers increased the ratio of red light in the overall spectrum, they recorded a linear decrease in yield. Compared to spectra with higher blue, red and far-red wavelengths, Merlice grown under broader spectrum lights yielded increases in fruit weight as high as 13 percent. Other tomato cultivars grown under broad-spectrum saw yield increases up to 14 percent.
Cannabis
Fluence conducted individual studies with WUR and Texas Original Compassionate Cultivation (TOCC), respectively. In the TOCC study, researchers studied Type I, Type II and Type III cannabis response to broad-spectrum R4, R6 and R8 under high PPFD. In each case, broad-spectrum R4 generated the most dry weight per plant. In Type I cannabis, PhysioSpecTM BROAD R4 generated 17 percent higher yields than the next highest yielding spectral solution, R6. Cannabis grown under broad-spectrum R4 also significantly improved morphology compared to plants cultivated under R6 or R8. Plants grown under broad-spectrum R4 were free of photobleaching in their upper buds, a development that typically occurs in plants grown with a higher fraction of red light.
In the WUR study, researchers found that in some cultivars, monoterpene and cannabinoid content, including THC, CBD and CBG, is significantly inversely proportional to the fraction of red light in the production spectrum. With these cultivars, R4 induced a 20 percent increase in cannabinoid compounds compared to spectra with red light ratios as high as 90 percent or more.
“The results of the TOCC and WUR intensity and spectrum studies are important for cannabis cultivators for two reasons,” Dr. Hawley said. “First, there is rarely a scenario in which they should grow cannabis under low PPFD. Our research continues to emphasize how much more beneficial it is to grow cannabis under higher PPFDs. Second, watch your red light ratio. There are a couple very specific cultivars and production situations that could benefit from narrow-band or high red/far-red and blue wavelengths. But it can also have detrimental effects on cannabinoid content, terpene ratios, yield and morphology, and would raise the risk of significant photobleaching of the canopy. That’s why we generally recommend growing cannabis with broad-spectrum under high PPFD.”
Bell pepper
Fluence also conducted studies with bell peppers at the Harrow Research and Development Centre in Ontario, Canada led by Dr. Xiuming Hao and Dr. Jason Lanoue. The collaborative research on bell pepper found that fruit quality significantly increased in Gina and Eurix cultivars under broad-spectrum lighting. Peppers grown under broader spectrum light increased average fruit size by up to 15 percent compared to others with higher blue and red wavelengths. An increase in the dry matter content—which is largely associated with fruit quality—also increased with increasing green light. It was also found that broad-spectrum lighting strategies proved the consistency of week-to-week production by leveling out a traditionally flush-prone crop cycle.
“Time and time again, our research with leading institutions around the world is proving that there is no universal spectral strategy for cultivators,” said David Cohen, CEO at Fluence. “For many crops and cultivars, however, it’s also showing the holistic benefits of broad-spectrum white light not just for the crop, but for a cultivator’s entire operation. That’s why we at Fluence have a multilayered approach to how we work with our cultivators. We continue to invest heavily in industry-leading research around the world. We provide cultivators with boots-on-the-ground expertise and experience in the form of our horticulture services team, and we identify the right light fixture and spectral strategy to help cultivators achieve their most important goals.”
Fluence’s ongoing global research initiatives include additional studies on strawberry, lettuce and cucumber cultivation. To learn more about Fluence and discover its latest research results, visit www.fluence.science.
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM, creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005279/en/
Contact information
For Fluence, Emma Chase
pr@fluencebioengineering.com
C: 512-917-4319
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 14:13:00 EEST | Press release
Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment across all three destinations reflects that conviction — we build for decades, and Oman is a country we intend to grow with in all circumstances.” — Naguib S. Sawiris, Chairm
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 14:00:00 EEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
